[The first batch of Novo Nordisk ultra long-acting insulin in the world is expected to be within two months] A few days ago, the Commission on Human Medicines (CHMP) of the European Drug Administration adopted a positive opinion, suggesting that Awiqli (a weekly preparation of basic insulin, Icodec insulin) be given a marketing license for the treatment of adult diabetes. Novo Nordisk (NVO.US) is expected to receive the final market approval from the European Commission within approximately two months. In addition to the European Union, Novo Nordisk also completed the listing application submission to the US FDA and Chinese regulatory authorities in the second quarter of 2023, and is currently waiting for the review results to be announced.